149 Bio

149 Bio, operating as AlloSite Therapeutics, is a clinical-stage biotechnology company focused on developing allosteric agonists of integrin receptors to treat kidney and immune-mediated diseases. The company utilizes its proprietary CellStaple platform, an AI-driven discovery engine, to identify novel small molecules and antibodies that activate integrins rather than inhibiting them. Its lead candidate, ONT01 (formerly GB1275), is an oral CD11b activator currently in Phase 1/2 development for Lupus Nephritis. 149 Bio is also advancing a preclinical program targeting integrin alpha3beta1 for the treatment of focal segmental glomerulosclerosis (FSGS). The company was founded by Dr. Vineet Gupta, a leading expert in integrin biology and allosteric modulation.